Roche's Innovative Drug Engine ‘Firing On All Cylinders’
Pharma Head Used Q1 To Flag Catalysts, Early Projects
Executive Summary
Roche’s Q1 update highlighted some key coming drug catalysts and early stage clinical efforts, including those for a potential COVID pill and for targeted cancer vaccines.
You may also be interested in...
Roche Hopes To Gain Broad Market For Tecentriq In Adjuvant NSCLC
An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.
Roche Warns On Anti-Trust Zeal While Posting Painful Q1
Biosimilar erosion and slack drugs sales caused by the pandemic depressed Roche’s first quarter pharma revenue while its diagnostics unit saw sales soar on COVID testing.
Roche Shelves Phase III Huntington's Candidate Tominersen
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.